ข่าวประชาสัมพันธ์ cardiovascular risk

Oral semaglutide demonstrated cardiovascular safety in people with type 2 diabetes and established cardiovascular disease or high cardiovascular risk in PIONEER 6 trial

Novo Nordisk today announced that the PIONEER 6 trial achieved its primary endpoint by demonstrating non-inferiority of major adverse cardiovascular events (MACE) with oral semaglutide compared with placebo, both in addition to standard of care. The primary endpoint was defined as the MACE composite outcome of the first occurrence of cardiovascular death, non-fatal myocardial infarction or non-fatal stroke and non-inferiority for cardiovascular safety of oral semaglutide versus placebo was

12 มิถุนายน 2562 08:50 น.

American College of Cardiology recommends empagliflozin as preferred SGLT2 inhibitor for adults with type 2 diabetes and established cardiovascular disease in new Expert Consensus Decision Pathway

A new Expert Consensus Decision Pathway issued by the American College of Cardiology (ACC) recommends... พ.ย. 61

Latest state-of-the-art health check-up technology comes to Thailand — Verita Health MahaNakhon (VMH) is introducing "Verita Wisdom", a new 360° state-of-... ต.ค. 61

Ozempic(R) Consistently Reduced the Risk of Major Cardiovascular Events Across Type 2 Diabetes Populations at High CV Risk Regardless of Prior CV Events at Baseline

Ozempic(R) (semaglutide) consistently reduced the risk of the composite outcome of time to first occurrence of non-fatal heart attack,... ส.ค. 61

Interim Results of First-Ever Global Survey Show People with Type 2 Diabetes Underestimate their Cardiovascular Risk

- Globally, cardiovascular disease (CVD) is the most common cause of death in people with type 2 diabetes[1] - 1 in 3 respondents considered themselves to be at low risk of CVD[2] - 1... ธ.ค. 60

Experts and Representatives From Leading International Health-Care Organizations Call to Stop the Hypertension Pandemic, a Worldwide Silent Killer

A Working Group of representatives from seven international health-care organizations call for improved blood pressure (BP) goal rate levels of patients... ก.พ. 51

New Data Show Xenical(R) Significantly Reduces Cardiovascular Risk and More Than Doubles Weight Loss Achieved in Overweight and Obese People

The weight loss medication Xenical(R) (orlistat 120mg) significantly reduces weight and improves cardiovascular risk factors such as blood pressure, glycaemic... เม.ย. 50

DATA DEMONSTRATE IMPACT OF WEIGHT LOSS WITH SIBUTRAMINE ON CARDIOVASCULAR RISK FACTORS FOR OBESE PATIENTS

Bangkok--Jun 4--Weber Shandwick (Thailand) Data Address Positive Impact of Weight Loss with Sibutramine On Cardiovascular Risk Factors of Metabolic Syndrome, Left Ventricular Mass, and Predicted... มิ.ย. 47